Pfizer to close two manufacturing in India

Pfizer to close two manufacturing in India

January 17, 2019 347

Pfizer has announced its IKKT and Aurangabad plants in India will close ‘as soon as possible in 2019’ in a move affecting almost 6% of its manufacturing workforce.

The two sites have already ceased production, Pfizer confirmed, after a review found the sites were ‘not viable’ following ‘very significant long term loss of product demand’. IKKT, near Chennai, accounts for around 1000 employees in Pfizer’s 30,000-strong global manufacturing staff, with a further 700 in Aurangabad. The plants focused solely on antibiotic drugs for export, with IKKT specialising in injectable cephalosporin and Maxipime, and both plants producing penems and penicillin.

 

 

 

Both sites were acquired by the pharma giant in its $17 billion (£11 billion) buyout of Hospira in 2015. The IKKT plant temporarily suspended operations last year after a visit from the US Food and Drug Administration, which found problems with its microbiology laboratory, standard operating procedures and discrepancies in test sample weights.

The closures come three years after operations ceased at Pfizer’s site in Thane, which was initially commissioned in the 1960s. However, Pfizer stated it remained committed to its presence in India, such as its current expansion at its Vizag (Visakhapatnam) site, which exports to the US ‘and eventually we expect to Canada’.

 

 

 

Information source: https://www.chemistryworld.com/news/pfizer-to-close-two-manufacturing-plants-in-india/3010000.article

Block ?

If this page is in your subscriptions, then it will be removed. You will not see this page. If you want to unblock a user, go to the settings, the list of blocked users and click unblock

Complain

The user will not know who exactly sent the complaint

Delete Company

The user will not know who exactly sent the complaint

Notifications

You Have 112 readed notifications

CHATS

Select chat category

×